Skip to main content
. Author manuscript; available in PMC: 2011 Sep 15.
Published in final edited form as: Cancer Res. 2010 Aug 31;70(18):7155–7165. doi: 10.1158/0008-5472.CAN-10-0668

Figure 2. Pro-apoptotic TAp73 and its target genes are selectively upregulated in BRCA1-deficient ovarian carcinoma cells.

Figure 2

(A) Selective induction of Noxa in murine BRCA1-deficient (TBR) lines following cisplatin treatment (1μM, 48 hours), assessed by QRT-PCR. Error bars show SD for two independent experiments performed in triplicate. (B) Noxa, Puma, and p53AIP1 are selectively induced following cisplatin treatment (10μM, 72 hours) in UWB1.289 cells lacking BRCA1, as assessed by QRT-PCR. All values shown are relative to Vector/Vehicle cells. (C) Consistent upregulation of basal TAp73 but not ΔNp73 expression in BRCA1-deficient versus wild-type murine cells, as assessed by QRT-PCR. (D) Upregulation of TAp73 mRNA and protein is associated with BRCA1-deficiency in human ovarian carcinoma cells. Left, TAp73 QRT-PCR; right, IP/Immunoblot in UWB1.289 cells. Heavy chain (H-chain) is shown as a loading control.

HHS Vulnerability Disclosure